Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Taking Aim At Recurrence: Targeting Cancer Stem Cells To Stop Proliferation

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

An emerging field of oncology drug development offers the potential for eradicating all remaining cancer cells following treatment – and thus preventing recurrence – by targeting the so-called cancer stem cells that are thought to be involved in cancer proliferation, treatment resistance, and metastasis.

You may also be interested in...



The Hype And Hope Of Cancer Stem Cell Therapeutics

A wave of recent deals demonstrates a growing belief in the potential cancer stem cells might offer for more effective cancer therapies. Some say there’s more hope and hype than science behind the activity. As the science unfolds, fundamental questions have yet to be answered about the pathway to products, especially as drug developers train their lines of sight on solid tumors.

AACR’s “Most Likely To Succeed” Anticancer Technologies

The AACR report celebrates “paradigm-shifting technologies and research areas that could dramatically accelerate advances against all types of cancer.” Some of the advanced technologies that the association thinks are “likely to be successful” include:

AACR’s “Most Likely To Succeed” Anticancer Technologies

The AACR report celebrates “paradigm-shifting technologies and research areas that could dramatically accelerate advances against all types of cancer.” Some of the advanced technologies that the association thinks are “likely to be successful” include:

Related Content

Topics

UsernamePublicRestriction

Register

ID007083

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel